[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE602004029145D1 - Pyrazolopyridin-derivate - Google Patents

Pyrazolopyridin-derivate

Info

Publication number
DE602004029145D1
DE602004029145D1 DE602004029145T DE602004029145T DE602004029145D1 DE 602004029145 D1 DE602004029145 D1 DE 602004029145D1 DE 602004029145 T DE602004029145 T DE 602004029145T DE 602004029145 T DE602004029145 T DE 602004029145T DE 602004029145 D1 DE602004029145 D1 DE 602004029145D1
Authority
DE
Germany
Prior art keywords
pyrazolopyridine derivatives
pyrazolopyridine
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004029145T
Other languages
English (en)
Inventor
Rosales Carmen Almansa
Bernado Marina Virgili
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Palau Pharma SA
Original Assignee
Palau Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32930978&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602004029145(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from ES200300640A external-priority patent/ES2214150B1/es
Priority claimed from ES200300727A external-priority patent/ES2214976B1/es
Application filed by Palau Pharma SA filed Critical Palau Pharma SA
Publication of DE602004029145D1 publication Critical patent/DE602004029145D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE602004029145T 2003-02-27 2004-02-27 Pyrazolopyridin-derivate Expired - Lifetime DE602004029145D1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ES200300640A ES2214150B1 (es) 2003-02-27 2003-02-27 "nuevos derivados de pirazolopiridinas".
ES200300727A ES2214976B1 (es) 2003-03-14 2003-03-14 "nuevos derivados de pirazolopiridinas".
ES200302504 2003-10-27
PCT/EP2004/001974 WO2004076450A1 (en) 2003-02-27 2004-02-27 Pyrazolopyridine derivates

Publications (1)

Publication Number Publication Date
DE602004029145D1 true DE602004029145D1 (de) 2010-10-28

Family

ID=32930978

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004029145T Expired - Lifetime DE602004029145D1 (de) 2003-02-27 2004-02-27 Pyrazolopyridin-derivate

Country Status (30)

Country Link
US (3) US7468376B2 (de)
EP (1) EP1611131B1 (de)
JP (1) JP4814783B2 (de)
KR (1) KR101312736B1 (de)
AR (1) AR043416A1 (de)
AT (1) ATE481402T1 (de)
AU (1) AU2004215644B2 (de)
BR (1) BRPI0407811A (de)
CA (1) CA2515197C (de)
CL (1) CL2004000398A1 (de)
CY (1) CY1111544T1 (de)
DE (1) DE602004029145D1 (de)
DK (1) DK1611131T3 (de)
EC (2) ECSP056041A (de)
HK (1) HK1085214A1 (de)
HR (1) HRP20050682B1 (de)
IL (1) IL196021A (de)
IS (1) IS2875B (de)
MX (1) MXPA05009069A (de)
NO (1) NO331917B1 (de)
NZ (1) NZ541836A (de)
PE (1) PE20050521A1 (de)
PL (1) PL378296A1 (de)
PT (1) PT1611131E (de)
RS (1) RS51768B (de)
RU (1) RU2359971C2 (de)
SI (1) SI1611131T1 (de)
TW (1) TWI325865B (de)
UA (1) UA81453C2 (de)
WO (1) WO2004076450A1 (de)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004029145D1 (de) * 2003-02-27 2010-10-28 Palau Pharma Sa Pyrazolopyridin-derivate
ES2241496B1 (es) * 2004-04-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridina.
AR050188A1 (es) * 2004-08-03 2006-10-04 Uriach Y Compania S A J Compuestos heterociclicos condensados utiles en terapia como inhibidores de quinasas p38 y composiciones farmaceuticas que los contienen
GB0427604D0 (en) * 2004-12-16 2005-01-19 Novartis Ag Organic compounds
FR2880891B1 (fr) * 2005-01-19 2007-02-23 Aventis Pharma Sa Pyrazolo pyridines substituees, compositions les contenant, procede de fabrication et utilisation
PE20061119A1 (es) 2005-01-19 2006-11-27 Aventis Pharma Sa PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie
CN101243080A (zh) * 2005-06-27 2008-08-13 阿姆布里利亚生物制药公司 作为hiv整合酶抑制剂的吡唑并[3，4-b]吡啶-2-基]-苯甲酸衍生物
RS50821B (sr) * 2005-06-27 2010-08-31 Sanofi-Aventis Derivati pirazolopiridina kao inhibitori beta-adrenergičnog receptora kinaze 1
ES2270715B1 (es) 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
FR2889526B1 (fr) 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
CA2619365A1 (en) 2005-08-22 2007-03-01 Amgen Inc. Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators
MX2008002383A (es) 2005-08-25 2008-03-18 Hoffmann La Roche Pirazol fusionado como inhibidores de proteinas cinasas activadas por mitogenos p38.
RU2008110941A (ru) * 2005-08-25 2009-09-27 Ф.Хоффманн-Ля Рош Аг (Ch) ИНГИБИТОРЫ КИНАЗЫ p38 МАР И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
KR20080031496A (ko) * 2005-09-02 2008-04-08 화이자 인코포레이티드 히드록시 치환된 1ｈ-이미다조피리딘 및 방법
ES2274712B1 (es) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
EP1948657A1 (de) * 2005-11-15 2008-07-30 Vertex Pharmaceuticals Incorporated Als kinase-hemmer verwendbare azaindazole
EP1932845A1 (de) * 2006-12-15 2008-06-18 Bayer Schering Pharma Aktiengesellschaft 3-H-Pyrazolopyridine und Salze davon, diese enthaltende pharmazeutische Zusammensetzungen , Verfahren zur ihrer Herstellung und ihre Verwendung
CL2007003627A1 (es) * 2006-12-15 2008-07-25 Bayer Schering Pharma Ag Compuestos derivados de 3-h-pirazolopiridinas; metodo de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades de crecimiento vascular desregulado tal como leucemia mielogena aguda, retinopatia, artritis reumatoide, psorias
WO2008104473A2 (en) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag Pyrazolopyriidine derivatives and their use as kinase inhibitors
EP1992344A1 (de) 2007-05-18 2008-11-19 Institut Curie P38 Alpha als therapeutisches Target für Erkrankungen, die mit einer FGFR3- Mutation assoziiert sind
WO2009055033A1 (en) * 2007-10-26 2009-04-30 Amgen Inc. Pyrazolo-pyridinone derivatives and methods of use
EP2070929A1 (de) 2007-12-11 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Alkynylarylverbindungen und Salze davon, pharmazeutische Zusammensetzungen damit sowie Verfahren zu ihrer Herstellung und Verwendung
WO2009095752A1 (en) * 2008-01-29 2009-08-06 Glenmark Pharmaceuticals, S.A. Fused pyrazole derivatives as cannabinoid receptor modulators
WO2010093595A1 (en) 2009-02-10 2010-08-19 E. I. Du Pont De Nemours And Company Fungicidal 2-pyridones
WO2010111527A1 (en) * 2009-03-26 2010-09-30 Plexxikon, Inc. Pyrazolo [ 3, 4 -b] pyridines as kinase inhibitors and their medical use
US20110034441A1 (en) * 2009-08-10 2011-02-10 Epitherix, Llc Indazoles as wnt/b-catenin signaling pathway inhibitors and therapeutic uses thereof
US8252812B2 (en) 2009-08-10 2012-08-28 Samumed, Llc Indazole inhibitors of the WNT signal pathway and therapeutic uses thereof
US8846673B2 (en) 2009-08-11 2014-09-30 Bristol-Myers Squibb Company Azaindazoles as kinase inhibitors and use thereof
FR2951172B1 (fr) * 2009-10-13 2014-09-26 Pf Medicament Derives pyrazolopyridines en tant qu'agent anticancereux
EP2515655B1 (de) 2009-12-21 2015-08-05 Samumed, LLC 1h-pyrazolo[3,4-beta]pyridine und therapeutische verwendung davon
EP2593453B1 (de) 2010-07-15 2014-09-17 Bristol-Myers Squibb Company Azaindazolverbindungen
CN102617548A (zh) * 2011-01-31 2012-08-01 北京赛林泰医药技术有限公司 作为gpr受体激动剂的双环杂芳基化合物及其组合物和应用
CA2826651A1 (en) 2011-02-24 2012-08-30 Cephalon, Inc. Substituted aromatic sulfur compounds and methods of their use
PL2755483T3 (pl) 2011-09-14 2019-06-28 Samumed, Llc Indazolo-3-karboksyamidy i ich zastosowanie jako inhibitorów szlaków sygnalizacji WNT/B-kateniny
PH12017500997A1 (en) 2012-04-04 2018-02-19 Samumed Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
MY173049A (en) * 2012-05-04 2019-12-20 Samumed Llc 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
RU2495039C1 (ru) * 2012-07-31 2013-10-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Пермский государственный национальный исследовательский университет" МЕТИЛ 3-МЕТИЛ-5-[2-(4-АРИЛАМИНО)-2-ОКСОАЦЕТИЛ]-1,6-ДИФЕНИЛ-1Н-ПИРАЗОЛО[3,4-b]ПИРИДИН-4-КАРБОКСИЛАТЫ И МЕТИЛ 3-МЕТИЛ-5-[2-(4-АРИЛАМИНО)-2-ОКСОАЦЕТИЛ]-6-СТИРИЛ-1-ФЕНИЛ-1Н-ПИРАЗОЛО[3,4-b]ПИРИДИН-4-КАРБОКСИЛАТЫ И СПОСОБ ИХ ПОЛУЧЕНИЯ
WO2014110086A2 (en) 2013-01-08 2014-07-17 Samumed, Llc 3-(benzoimidazol-2-yl)-indazole inhibitors of the wnt signaling pathway and therapeutic uses thereof
CN104230922B (zh) * 2013-06-19 2016-12-28 中国科学院上海药物研究所 一类五元杂环并吡啶类化合物及其制备方法和用途
SG11201602937UA (en) 2013-10-17 2016-05-30 Blueprint Medicines Corp Compositions useful for treating disorders related to kit
WO2016040185A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof
WO2016040182A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine and therapeutic uses thereof
WO2016040190A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
WO2016040193A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
WO2016040180A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040181A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040184A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040188A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2017023972A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10166218B2 (en) 2015-08-03 2019-01-01 Samumed, Llc 3-(1H-indol-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
WO2017024004A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10188634B2 (en) 2015-08-03 2019-01-29 Samumed, Llc 3-(3H-imidazo[4,5-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017023986A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-indol-2-yl)-1h-indazoles and therapeutic uses thereof
WO2017023987A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
US10285982B2 (en) 2015-08-03 2019-05-14 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
US10226453B2 (en) 2015-08-03 2019-03-12 Samumed, Llc 3-(1H-indol-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017023984A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
WO2017023989A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017024015A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10519169B2 (en) 2015-08-03 2019-12-31 Samumed, Llc 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017024021A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
WO2017023996A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
US10383861B2 (en) 2015-08-03 2019-08-20 Sammumed, LLC 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
WO2017024010A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
US10231956B2 (en) 2015-08-03 2019-03-19 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
KR20180080262A (ko) 2015-11-06 2018-07-11 사뮤메드, 엘엘씨 골관절염의 치료
WO2017151409A1 (en) 2016-02-29 2017-09-08 University Of Florida Research Foundation, Incorporated Chemotherapeutic methods
US20170275662A1 (en) * 2016-03-22 2017-09-28 The Quaker Oats Company Method and Apparatus for Controlled Hydrolysis
PL3464285T3 (pl) 2016-06-01 2023-02-06 Biosplice Therapeutics, Inc. Sposób wytwarzania n-(5-(3-(7-(3-fluorofenylo)-3h-imidazo[4,5-c]pirydyn-2-ylo)-1h-indazol-5-ilo)pirydyn-3-ylo)-3-metylobutanoamidu
WO2018075858A1 (en) 2016-10-21 2018-04-26 Samumed, Llc Methods of using indazole-3-carboxamides and their use as wnt/b-catenin signaling pathway inhibitors
JP2019533702A (ja) 2016-11-07 2019-11-21 サミュメッド リミテッド ライアビリティ カンパニー 単回用量の調整済み注射用製剤
WO2018183712A1 (en) 2017-03-31 2018-10-04 Blueprint Medicines Corporation Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr
JOP20190278A1 (ar) 2017-05-31 2019-11-28 Novartis Ag مركبات 5، 6-ثنائية الحلقة مندمجة وتركيبات لعلاج الأمراض الطفيلية
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
KR20200066655A (ko) 2017-10-05 2020-06-10 풀크럼 쎄러퓨틱스, 인코포레이티드 DUX4의 발현을 저감시키기 위한 p38 저해제의 용도
GB201721793D0 (en) * 2017-12-22 2018-02-07 Hvivo Services Ltd Methods and compunds for the treatment or prevention of hypercytokinemia and severe influenza
SG11202111244XA (en) 2019-04-12 2021-11-29 Blueprint Medicines Corp Pyrrolotriazine derivatives for treating kit- and pdgfra-mediated diseases
PT3856341T (pt) 2019-04-12 2023-12-12 Blueprint Medicines Corp Formas cristalinas de (s)-1-(4-fluorofenil)-1-(2-(4-(6-(1- metil-1h-pirazol-4-il)pirrolo[2,1-f][1,2,4]triazin-4- il)piperazinil)pirimidin-5-il)etan-1-amina e métodos de preparação
WO2021067967A1 (en) * 2019-10-04 2021-04-08 University Of Kentucky Research Foundation Preparation of pyrazolo[3,4-b]pyridines as antimalarials
WO2024150014A1 (en) 2023-01-13 2024-07-18 Poolbeg Pharma (UK) Limited Medicinal products and methods for the alleviation of cancer immunotherapy-associated cytokine release syndrome

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3403158A (en) 1966-03-11 1968-09-24 Upjohn Co 1h-pyrazolo[3, 4-b]pyridines
US4264603A (en) * 1980-03-17 1981-04-28 Sterling Drug Inc. 5-(Pyridinyl)-1H-pyrazolo[3,4-b]pyridine-3-amines, their use as cardiotonics and their preparation
US4361568A (en) 1981-04-28 1982-11-30 Sterling Drug Inc. 5-(Pyridinyl)-1H-pyrazolo[3,4-b]pyridin-3-amines and their cardiotonic use
US4375467A (en) * 1981-09-28 1983-03-01 Sterling Drug Inc. 5-(Pyridinyl)-1H-pyrazolo[3,4-b] pyridines and their cardiotonic use
KR100228949B1 (ko) 1993-07-06 1999-11-01 디. 제이. 우드, 스피겔 알렌 제이 이환상 테트라하이드로 피라졸로피리딘
CA2314355A1 (en) 1997-12-13 1999-06-24 Bristol-Myers Squibb Company Use of pyrazolo ¢3,4-b! pyridine as cyclin dependent kinase inhibitors
US6559152B2 (en) * 1998-10-13 2003-05-06 Dupont Pharmaceuticals Company 6-substituted pyrazolo[3,4-d]pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
CZ20011556A3 (cs) 1998-11-03 2001-11-14 Glaxo Group Limited Pyrazolopyridinové deriváty
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
US6608072B1 (en) 1999-10-27 2003-08-19 Novartis Ag Thiazole compounds and their pharmaceutical use
GB9929685D0 (en) 1999-12-15 2000-02-09 Merck Sharp & Dohme Therapeutic agents
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
JP2004507455A (ja) * 2000-04-25 2004-03-11 ブリストル−マイヤーズ　スクイブ　カンパニー サイクリン依存性キナーゼ阻害剤としての、５−チオ−、スルフィニル−およびスルホニルピラゾロ［３，４−ｂ］−ピリジンの用途
ATE277933T1 (de) 2000-06-06 2004-10-15 Pfizer Prod Inc Thiophenverbindungen zur verwendung als antikrebsmittel
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
EP1319001A1 (de) 2000-09-22 2003-06-18 Smithkline Beecham Plc Pyrazolopyridine und pyrazolopyridazine als antidiabetika
AR031176A1 (es) * 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
CN1630656A (zh) * 2001-02-02 2005-06-22 三菱制药株式会社 二氢吡唑并吡啶化合物及其制药用途
ES2263779T3 (es) * 2001-03-14 2006-12-16 Grunenthal Gmbh Pirazolopirimidinas sustituidas.
GB0124848D0 (en) 2001-10-16 2001-12-05 Celltech R&D Ltd Chemical compounds
WO2003068773A1 (en) * 2002-02-12 2003-08-21 Glaxo Group Limited Pyrazolopyridine derivatives
US7186716B2 (en) 2002-08-12 2007-03-06 Sugen, Inc. 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors
UA81790C2 (uk) 2002-12-19 2008-02-11 Фармация Италия С.П.А. Заміщені піролопіразольні похідні як інгібітори кінази
DE602004029145D1 (de) * 2003-02-27 2010-10-28 Palau Pharma Sa Pyrazolopyridin-derivate
CA2522430A1 (en) 2003-04-24 2004-11-11 Merck & Co., Inc. Inhibitors of akt activity
AR044129A1 (es) 2003-05-06 2005-08-24 Altana Pharma Ag Compuestos intermedios de imidazopiridina. proceso de preparacion.
JP2007504243A (ja) * 2003-09-03 2007-03-01 ニューロジェン・コーポレーション ５−アリール−ピラゾロ［４，３−ｄ］ピリミジン類、ピリジン類、ピラジン類及び関連化合物

Also Published As

Publication number Publication date
HK1085214A1 (en) 2006-09-29
IS7939A (is) 2005-07-14
CY1111544T1 (el) 2015-08-05
IS2875B (is) 2014-04-15
CA2515197A1 (en) 2004-09-10
RU2005130020A (ru) 2006-07-10
DK1611131T3 (da) 2011-01-17
RS51768B (sr) 2011-12-31
NO20053647L (no) 2005-10-18
AU2004215644B2 (en) 2010-09-02
AU2004215644A1 (en) 2004-09-10
MXPA05009069A (es) 2005-10-19
US20090005377A1 (en) 2009-01-01
PE20050521A1 (es) 2005-09-11
ECSP12006041A (es) 2012-12-28
NO331917B1 (no) 2012-04-30
CL2004000398A1 (es) 2005-03-18
PT1611131E (pt) 2010-12-20
KR20060002782A (ko) 2006-01-09
CA2515197C (en) 2011-10-18
IL196021A0 (en) 2009-02-11
BRPI0407811A (pt) 2006-02-14
HRP20050682B1 (hr) 2014-09-12
US8536194B2 (en) 2013-09-17
KR101312736B1 (ko) 2013-09-27
EP1611131B1 (de) 2010-09-15
ATE481402T1 (de) 2010-10-15
JP4814783B2 (ja) 2011-11-16
US20090286983A1 (en) 2009-11-19
TWI325865B (en) 2010-06-11
NO20053647D0 (no) 2005-07-27
HRP20050682A2 (en) 2006-05-31
IL196021A (en) 2011-10-31
JP2006519205A (ja) 2006-08-24
TW200504061A (en) 2005-02-01
WO2004076450A8 (en) 2005-09-01
RS20050609A (en) 2007-12-31
AR043416A1 (es) 2005-07-27
UA81453C2 (en) 2008-01-10
EP1611131A1 (de) 2006-01-04
US7468376B2 (en) 2008-12-23
US20060167040A1 (en) 2006-07-27
SI1611131T1 (sl) 2011-03-31
NZ541836A (en) 2008-12-24
WO2004076450A1 (en) 2004-09-10
ECSP056041A (es) 2006-01-27
RU2359971C2 (ru) 2009-06-27
PL378296A1 (pl) 2006-03-20

Similar Documents

Publication Publication Date Title
DK1611131T3 (da) Pyrazolopyridin-derivater
CY2014018I2 (el) Kαρβαμιδο - υποκατεστημενες πυραζολοπυριδινες
ATE340782T1 (de) Piperidinbenzolsulfonamidderivate
ATE420066T1 (de) Amidoacetonitrilderivate
ATE352550T1 (de) Chinazolinderivate
ATE415400T1 (de) Pyrazolopyridinderivate
ATE478870T1 (de) Spiroindolinpiperidinderivate
DK1556385T3 (da) Heterocyclocarboxamid-derivater
ATE450506T1 (de) Indol-3-schwefelderivate
ATE467631T1 (de) Chinuclidinamidderivate
IS7720A (is) Píperidín-N-oxíð-afleiður
ATE438644T1 (de) Chinazolinderivate
DK2248807T3 (da) N-Phenyl-2-pyrimidinaminderivater
DK1606277T3 (da) Imidazol-4-yl-ethynyl-pyridinderivater
IS8364A (is) N-þíasól-2-ýl-bensamíð afleiður
IS8180A (is) Nýjar besímídasólafleiður
ATE412651T1 (de) Pyrrolopyridinderivate
DE60307512D1 (de) 3h-chinazoline -4-on derivaten
ATE423771T1 (de) Tetrahydrochinolinderivate
ATE449064T1 (de) Amidoacetonitrilderivate
IS8045A (is) Púrín-6-ón-afleiður
DE50306277D1 (de) 4-alkyl-/4-alkenyl-/4-alkinylmethyl/-1-arylcyclohexylamin-derivate
IS7991A (is) Setnar p-díamínóbensen afleiður
IS7906A (is) Afleiður própargýl-tríflúorómetoxý-amínó-benzóþíazóls
DK1503988T3 (da) Fredericamycin-derivater